11.36
-0.27(-2.32%)
Currency In USD
| Previous Close | 11.63 |
| Open | 11.69 |
| Day High | 11.78 |
| Day Low | 11.31 |
| 52-Week High | 13.06 |
| 52-Week Low | 8.73 |
| Volume | 4.37M |
| Average Volume | 6.29M |
| Market Cap | 7.72B |
| PE | -15.15 |
| EPS | -0.75 |
| Moving Average 50 Days | 11.15 |
| Moving Average 200 Days | 11.18 |
| Change | -0.27 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $1,092.31 as of July 16, 2025 at a share price of $11.36. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 3 years ago, it would be worth $2,685.58 as of July 16, 2025 at a share price of $11.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
GlobeNewswire Inc.
Jun 09, 2025 8:05 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, t
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
GlobeNewswire Inc.
May 15, 2025 8:10 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 29, 2025, to report its financial results for
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire Inc.
Mar 19, 2025 11:45 AM GMT
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64%